All News
Decreasing immunogenicity, improving efficacy of pegloticase in gout
At #ACR20 three different medications are reviewed in different studies to decrease the immunogenicity of pegloticase – Methotrexate, Azathioprine and Mycophenolate Mofetil.
Read Article
Mitigating Immunogenicity When Using Uricase Therapies as ULT
ACR20 convergence highlights a shift in gout management and uric acid lowering therapy (ULT). The new biologics pegdriticase and pegloticase are associated with risk of immunogenicity and loss of biological effects.
Read Article
#Multimorbidity in #RheumaticDisease: Abs#1466:
-Highly prevalent across RA, PsA, gout & OA
-Highest burden in #gout
Important study highlighting need to recognise burden of MM in #rheumatology patients for holistic optimised management.
#ACR20 @RheumNow
https://t.co/esinnHoUME https://t.co/bApXfx7hOU
Mrinalini Dey DrMiniDey ( View Tweet)
Dr England presents on multimorbidity in RA, PsA, gout, and OA within RISE registry. Highly prevalent in all 4 but most pronounced in gout and RA. Critical to recognise and manage. @rheumnow #ACR20 Abstr#1466 https://t.co/XtwIfJnVXV
Richard Conway RichardPAConway ( View Tweet)
Study incl 1243 #SLE patients finds excess risk of #cardiovascular events is underestimated by CVD prediction tools- the underestimation may be increased in those with more severe disease activity.
Abs#1286 #ACR20 @RheumNow
https://t.co/6FZvxE02CF
Mrinalini Dey DrMiniDey ( View Tweet)
So excited to check out RheumNow’s ACR Mid-Meeting Recap live right now with Dr. Jack Cush (@rheumnow), Dr. Arthur Kavanaugh, Dr. Michale Pillinger, and Dr. Bella Mehta! #ACR20
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Crystal Arthritis and Gout Highlights at ACR: Dr. Nicola Dalbeth
Gout specialist Dr. Nicola Dalbeth from Aukland, New Zealand provides a preview perspective on crystal arthritis and gout studies and sessions at #ACR20.
https://t.co/QfVSpeVXlf https://t.co/cBwKF5P5eb
Links:
Dr. John Cush RheumNow ( View Tweet)
Reducing Immunogenicity of Pegloticase (RECIPE) w/ concomitant use of MMF in pts w/ refractory gout is a phase II double blind RCT that shows sustained serum urate lowering effect in addition to decrease in monthly rate of flares. #ACRbest #Abst0952 @RheumNow Practice changing? https://t.co/Z7GwCXZftE
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate Levels Following Multiple Ascending Once-Daily Doses in Healthy Subject Volunteers https://t.co/fRB2zuKl5J #gout #uricosuric a novel uricosuric agent
Peter Nash drpnash ( View Tweet)
Based on RECIPE, how many of you will use MMF concomitantly with start of pegloticase in treating refractory gout patients? #ACR20 @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dr Khanna presents RECIPE RCT of MMF to reduce immunogenicity of pegloticase. Sustained urate response ≤6mg/dL at 24 weeks 68% with MMF compared to 30% in placebo. @rheumnow #ACR20 Abstr#952 #ACRbest https://t.co/64nN5AqK3W
Richard Conway RichardPAConway ( View Tweet)
Dr Merriman presents on role of diet in gout. It is minor, especially compared to urate lowering therapy. Average attributable fraction approximately 10-fold greater for ULT than following healthy-eating guidelines. @rheumnow #ACR20 Abstr#951 https://t.co/1tftswOEJq
Richard Conway RichardPAConway ( View Tweet)
Dr Cai presents risk of CVD in gout in study 450,000 patients. Gout was independently associated with an increased risk of CVD events HR = 1.24 for women; 1.21 for men. @rheumnow #ACR20 Abstr#950 #ACRbest https://t.co/089aKtN5a7
Richard Conway RichardPAConway ( View Tweet)
Evidence-Based Guidance for Optimizing Gout #ACR20 Reminding us of cardioprotective effect of anti-inflammatory gout management with colchicine. https://t.co/TmsrRd2vFD
Jilaine Bolek Berquist BolekBerqui ( View Tweet)
Is diet important in gout control? #ACR20 @rheumnow
Richard Conway RichardPAConway ( View Tweet)
@RheumNow #acr20 abs0665 claim based database stdy of pegloticase/immunomodulation coadministration trends: use of co-immunomodulation ⬆️ from 1.2%-3.9% 2015- 2018 to 15.0% in 2019. 86%start immunomodulator within 30 days of first peg infusion. MTX most commonly used
Olga Petryna DrPetryna ( View Tweet)
@RheumNow #acr20 abs0690 ph2a trial: potent reduction of sUA w/URAT1 inhibitor AA882. 100% of pts sUA levels < 6 mg/dL &63% pts < 5 mg/dL compared to febuxostat 50% & 13% respectively. Even more remarkable reduction w/ AA882+febuxostat. Mild to moderate SEs. https://t.co/XrDJXEoC1j
Olga Petryna DrPetryna ( View Tweet)
@RheumNow #acr20 abs0600 a case control stdy of 545 CHF exacerbate admissions: pts w/gout flares median LoS 10 d vs 6 d w/out flare or gout at all. log LoS w gout flare 2.41 ± 0.96 vs 1.77 ± 0.90 w/out, p < 0.0001. Prevention of gout flares in CHF pts of essence #ACRbest https://t.co/8xiHHYxvsC
Olga Petryna DrPetryna ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow and its Faculty.
Dr. John Cush RheumNow ( View Tweet)
@RheumNow #acr20 abs 0649 PROTECT trial of pegloticase in 7 kidney transplant pts w/uncontrolled gout: 2-12 infusions, 2+immunosuppressants on board for transplant care. No change in eGFR, HAQ pain ⬇️by 33.8 at wk20. Alb/cr improved by >35%in 2pts. sUA< 1 mg/dL, no serious AEs https://t.co/f4tnFjMTe8
Olga Petryna DrPetryna ( View Tweet)
